Mabwell News

Maiwei Bio-U (688062): 9MW2821 debuted at ASCO, successful in innovative research and development

廣發證券May 29 00:00

Maiwei Biology (688062): High quality ADC platform company with good clinical data for multiple indications

天風證券May 26 00:00

Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progre

Zhitong FinanceApr 19 18:32

Maiwei Bio-U (688062): NECTIN-4 ADC multi-indication rapid clinical promotion

國信證券Apr 19 16:21

Maiwei Biology (688062): Analogs are entering the harvest period and the development of new drugs is being promoted efficiently

廣發證券Apr 18 11:16

Maiwei Biotech (688062): ADC released multiple data and commercialization of similar drugs in China progressed smoothly

德邦證券Apr 17 11:11

Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is prog

Zhitong FinanceApr 13 22:35

Maiwei Biotech (688062): Commercialization and capacity construction are steadily advancing, and the NECTIN-4 ADC multi-pipeline is progressing positively

華金證券Apr 13 00:00

Maiwei Bio-U (688062): NECTIN4 ADC shows excellent data in multiple cancer types

華西證券Apr 12 16:26

SDIC Securities released a research report on April 10 stating that Maiwei Biotech (688062.SH) was given a purchase rating and the target price was 47.95 yuan. The main reasons for the rating include: 1) NECTIN-4 ADC is worth looking forward to; 2) Long-a

Zhitong FinanceApr 11 07:24

Maiwei Biotech (688062) First Coverage Report: Core Product NECTIN-4 ADC Global Progress Leading Product Pipeline Collaborative Promotion at Home and Abroad

西部證券Mar 21 07:41

Maiwei Biotech (688062): Differential Innovation Accelerates NECTIN-4 ADC Leading Global Progress

德邦證券Mar 12 18:32

Maiwei Biotech (688062): NECTIN-4 ADC, an innovative pharmaceutical company with comprehensive capabilities, leads the way

國信證券Feb 1 07:51

Maiwei Bio-U (688062): NECTIN4ADC launches phase III innovation platform and continues to deliver

中信建投證券Dec 17, 2023 07:22

Maiwei Biotech (688062): BIOPHARMA can be expected to grow, innovation is beginning to shine

廣發證券Dec 10, 2023 00:00

Maiwei Biotech (688062): The rise of new ADC stars is optimistic about NECTIN-4 ADC's overseas market potential

安信證券Dec 6, 2023 07:22

Maiwei Bio-U (688062) Investment Value Analysis Report: NECTIN-4 ADC Leads Rapidly Growing Biopharmaceuticals in Biotech

中信證券Nov 9, 2023 19:57

Maiwei Biotech (688062): ADC drug clinical pipeline progress leads many BIC/FIC products with full potential

天風證券Oct 27, 2023 00:00

Maiwei Biotech (688062): NECTIN-4 ADC's latest data is excellent, future overseas licensing is worth paying attention to

安信證券Oct 26, 2023 13:56

Maiwei Biotech (688062): NECTIN-4 ADC shows BIC drug potential

華西證券Oct 26, 2023 00:00